Xanthine derivatives as a2b adenosine receptor antagonists
CA 2524778 C · Owner: Ibrahim, Prabha · Inventors: Kalla, Rao; Varkhedkar, Vaibhav; Perry, Thao
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Disclosed are compounds that are A2B adenosine receptor antagonists, useful for treating various disease states including asthma and , diarrhea. In general disclosed are compounds of Formula I or Formula II: (see formula Formula I) (see formula Formula II) wherein:, R1 and R2 are independently chosen from hydrogen optionally , substituted alkyl, or a group -D-E in which D is a covalent bond or alkylene and , E is alkoxy, cycloalkyl, aryl, heteroaryl heterocyclyl, alkenyl, or alkynyl, each of which is optionally substituted;, R3 is hydrogen optionally substituted alkyl or optionally substituted cycloalkyl;, X is optionally substituted arylene or heteroarylene; Y is a covalent bond or …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed May 6, 2003 and granted January 29, 2013. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended May 6, 2023.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by May 6, 2025.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.